



8th March, 2024

<p>To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Ref.: Scrip Code No. : 540701 (Equity) : 974556 (Debt)</p>	<p>To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p>Ref. : (i) Symbol – DCAL (ii) Series – EQ</p>
--	--

SUB.: DISCLOSURE PURSUANT TO REGULATIONS 30 and 51 OF SEBI (LODR) REGULATIONS, 2015: SUCCESSFULLY COMPLETION OF THE UNITED STATES FOOD AND DRUG ADMINISTRATION (US FDA) INSPECTION AT COMPANY’S BAVLA FACILITY

Dear Sir,

With reference to the captioned subject, we are pleased to inform you that the US-FDA inspection planned between 4th March, 2024 to 8th March, 2024 at the Company’s facility in Bavla, Ahmedabad, was successfully completed on 7th March, 2024.

The inspection was concluded with few procedural observations and the same will be addressed within the stipulated timelines.

No any serious issue was raised during the course for the entire inspection.

Thus, the Company’s facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the US FDA.

Kindly take this on your record.

Thanking You,

Yours faithfully,

For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary